Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah - Hebrew Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.

• Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.

Review of the hardback: '… this is a well-written book on a subject which is often found complicated and difficult … the book will be informative for the reader who wants a general review of the field of psychopharmacogenetics, but will also be useful for the reader who wants updated information on a specific topic …' European Journal of Clinical Pharmacology

Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah - Hebrew Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.

• Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.

Review of the hardback: '… this is a well-written book on a subject which is often found complicated and difficult … the book will be informative for the reader who wants a general review of the field of psychopharmacogenetics, but will also be useful for the reader who wants updated information on a specific topic …' European Journal of Clinical Pharmacology

Bernard Lerer is Professor of Psychiatry and Director of the Biological Psychiatry Laboratory at Hadassah - Hebrew Medical Center in Jerusalem. He is Director of the National Institute for Psychobiology in Israel, and Editor-in-Chief of the International Journal of Neuropsychopharmacology.

• Part I. Introduction: 1. Genes and psychopharmacology: exploring the interface Bernard Lerer; Part II. Clinical Background and Research Design: 2. From pharmacogenetics to pharmacogenomics of psychotropic drug response Anil K. Malhotra; 3. Neuropsychopharmacology: the interface between genes and psychiatric nosology Thomas A. Ban; 4. Methodological issues in psychopharmacogenetics Sheldon H. Preskorn; 5. Statistical approaches in psychopharmacogenetics Fabio Macciardi; Part III. Molecular Background: 6. The psychopharmacogenetic-neurodevelopmental interface in serotonergic gene pathways K. Peter Lesch, Jens Benninghoff and Angelika Schmitt; 7. RNA processing regulation and interindividual variation Colleen M. Niswender and Linda K. Hutchinson; Part IV. Pharmacokinetics: 8. Pharmacogenetics of psychotropic drug metabolism Vural Ozdemir, Angela D. M. Kashuba, Vincenzo S. Basile and James L . Kennedy; 9. Pharmacogenetics of chiral psychotropic drugs Pierre Baumann and Chin B. Eap; Part V. Specific Psychotropic Drugs and Disorders: 10. Clozapine response and genetic variation in neurotransmitter receptor targets David A. Collier, Maria J. Arranz, Sarah Osborne, Katherine J. Aitchison, Janet Munro, Dalu Mancama and Robert W. Kerwin; 11. Genetic factors underlying drug-induced tardive dyskinesia Ronnen H. Segman and Bernard Lerer; 12. Functional gene-linked polymorphic regions in pharmacogenetics Marco Catalano; 13. Alternative phenotypes and the pharmacogenetics of mood and anxiety disorders Emanuela Mundo and James L. Kennedy; 14. Pharmacogenetics of anxiolytic drugs and the GABA-benzodiazepine receptor complex Smita A. Pandit, Spilios V. Argyropoulous, Patrick G. Kehoe and David J. Nutt; 15. Genetic factors and long-term prophylaxis in bipolar disorder Martin Alda; 16. Genetic influences on responsiveness to anticonvulsant drugs Thomas N. Ferraro; 17. Apolipoprotein E as a marker in the treatment of Alzheimer's disease Keith Schappert, Pierre Sevigny and Judes Poirier; 18. Genetic variation and drug dependence risk factors Joel Gelernter and Henry Kranzler; Part VI. Pharmacogenetics and Brain Imaging: 19. Brain imaging and pharmacogenetics in Alzheimer's disease and schizophrenia Steven G. Potkin, James L. Kennedy and Vincenzo S. Basile; Part VII. Industry perspectives: 20. Pharmacogenetics in psychotropic drug discovery and development William Z. Potter, AnnCatherine Van Lone and Larry Altstiel; 21. High-throughput single nucleotide polymorphism genotyping Anne Shalom and Ariel Darvasi; Index.

Review of the hardback: '… this is a well-written book on a subject which is often found complicated and difficult … the book will be informative for the reader who wants a general review of the field of psychopharmacogenetics, but will also be useful for the reader who wants updated information on a specific topic …' European Journal of Clinical Pharmacology